2023 Partners



Lead Partner

Natera is a global leader in cell-free DNA (cfDNA) testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology and organ health. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and reliable tool for early, clinically meaningful rejection assessment. Renasight™ is a comprehensive, accessible renal genetics test for patients with chronic kidney disease. Learn more to help accelerate your research. 



MDI Bioscience

Expertise Partner

MDI Biological Laboratory is internationally recognized for pioneering contributions to the understanding of renal physiology and function. Today, we continue to play an important role in understanding the fundamental mechanisms of kidney damage and repair. MDI Bioscience, a division of MDI Biological Laboratory, now brings this expertise to drug discovery by creating target-specific research programs utilizing high throughput in vivo profiling in zebrafish, computational pharmacology, and simulated biological systems like organoids and organ-on-a-chip technology. We create tailored genetic and chemically-induced zebrafish models for early screening in whole organisms to complement invitro screens and provide greater confidence in the future viability of early-stage molecules.


fibrofind logo


Expertise Partner

FibroFind is a rapidly developing biomedical sciences companythat has a deep understanding of fibrosis biology and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to prevent fibrosis and halt disease. The business focus for FibroFind is their proprietary human fibrosis bioassays in Precision Cut Tissue Slices that provide a pre-clinical service for pharmaceutical and biotechnology companies developing medicines that target inflammation or fibrosis. Despite only beginning trading 3 years ago, FibroFind has already contributed towards new medicines entering into ongoing clinical trials.



Antaros Medical

Program Partner

Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.


AKF logo

American Kidney Fund

Program Partner

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease — from prevention through post-transplant living.





Exhibition Partner

MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 275 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used. In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing. Data readout of the TGFR Phase 3 Global Pivotal Study is expected in 2022.



SeaStar Medical has redefined how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs through novel solutions and services.

SeaStar Medical

Program Partner

SeaStar Medical is a medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.



Chinhook (002)

Chinook Therapeutics

Industry Partner

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial.